Following the positive opinion of the European Committee for Medicinal Products for Human Use, GlaxoSmithKIine Italy has applied to theAlpha (Italian Medicines Agency) for the introduction in the NHS of its vaccine for the prevention of cervical cancer. Cervical cancer is the second leading cause of death in women under 45 and is responsible for 270,000 dead a year. From Il Sole 24 Ore Sanita' of 10/08/2007 N. 31/32 7-20 AUGUST 2007
